Headache News and Research

Latest Headache News and Research

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Genzyme, a Sanofi company, today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.

15 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Nerve stimulation could stave off migraine attacks

Transcutaneous stimulation of the trigeminal nerve has shown promise as a treatment for migraine, according to results of a randomized controlled trial.

14 Feb 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

Tips on avoiding a Valentine's Day Headache

February 14 is right around the corner, and no one wants to spend Valentine's day, or the day after, with a severe headache and some of its accompaniments – nausea, vomiting, sensitivity to light and sound. And you certainly don't want your gift to be the culprit in producing a headache.

12 Feb 2013

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia.

10 Feb 2013

Migraine, epilepsy and genetics: an interview with Dr. Melodie Winawer

This work is the product of an extraordinary consortium called the Epilepsy Phenome/Genome project (EPGP). It is a consortium of 27 centres in the U.S. and internationally with several hundred physicians and staff who have worked together to enrol more than 4000 patients with epilepsy and their family members.

7 Feb 2013

Study: 10 to 15% of people with TIAs will experience strokes within three months

Each year, as many as 500,000 Americans experience mini strokes called transient ischemic attacks (TIAs). Symptoms quickly go away, usually within an hour, and many people don't seek treatment. But 10 to 15 percent of people who experience TIAs will experience full-blown strokes within three months, and 40 percent of these strokes will occur in the first 24 hours, according to an article by three Loyola University Medical Center neurologists in the journal Expert Review of Neurotherapeutics.

6 Feb 2013

ATI Neurostimulation System demonstrates clinical effectiveness in treating cluster headache

Autonomic Technologies, Inc. (ATI), the developer of the ATI Neurostimulation System designed for the treatment of severe headaches, today announced results of their clinical study in cluster headache, now published online in Cephalalgia.

5 Feb 2013

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

5 Feb 2013

Hyperion Therapeutics receives FDA approval for Ravicti to treat urea cycle disorders

The U.S. Food and Drug Administration today approved Ravicti (glycerol phenylbutyrate) for the chronic management of some urea cycle disorders (UCDs) in patients ages 2 years and older.

1 Feb 2013

Study supports hypothesis that disulfiram reduces drug consumption by blocking DβH

Disulfiram was the first medication approved for the treatment of alcoholism over 50 years ago. It works, at least in part, by preventing the metabolism of an alcohol by-product, acetaldehyde. High levels of acetaldehyde in the body quickly cause unpleasant symptoms, including nausea, vomiting, headache, and accelerated heart rate. Thus, disulfiram provides a very strong incentive to avoid drinking.

1 Feb 2013

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Pfizer Inc. said today that the United States District Court for the District of Delaware ruled that Pfizer's patent covering a method for using sirolimus, the active ingredient in RAPAMUNE®, for the inhibition of organ transplant rejection is valid and infringed.

31 Jan 2013

Pediatric migraine drugs show limited or no efficacy

There is limited evidence supporting the efficacy of trazodone and topiramate in the prevention of pediatric episodic migraine headaches, show results from a meta-analysis.

30 Jan 2013

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

The U.S. Food and Drug Administration today approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH).

30 Jan 2013

Childhood adversity raises comorbidity risk in bipolar disorder

Childhood adversity, including verbal, physical, or sexual abuse, is associated with the later development of multiple medical comorbidities in patients with bipolar disorder, researchers report.

29 Jan 2013

Sanofi announces availability of Auvi-Q in U.S. retail pharmacies

Sanofi announced today that Auvi-Q (epinephrine injection, USP) is now available in U.S. retail pharmacies nationwide with a prescription from a healthcare provider.

29 Jan 2013

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted approval for the expansion of the company's pneumococcal conjugate vaccine, Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for use in older children and adolescents aged 6 years through 17 years for active immunization for the prevention of invasive disease caused by the 13 Streptococcus pneumoniae serotypes contained in the vaccine.

28 Jan 2013

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.

28 Jan 2013

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

The U.S. Food and Drug Administration today approved three new related products for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin) tablets, Kazano (alogliptin and metformin hydrochloride) tablets, and Oseni (alogliptin and pioglitazone) tablets.

28 Jan 2013

Headache News and Research

Latest Headache News and Research

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Nerve stimulation could stave off migraine attacks

LASAG trial for severe influenza initiated

Tips on avoiding a Valentine's Day Headache

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Migraine, epilepsy and genetics: an interview with Dr. Melodie Winawer

Study: 10 to 15% of people with TIAs will experience strokes within three months

ATI Neurostimulation System demonstrates clinical effectiveness in treating cluster headache

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Hyperion Therapeutics receives FDA approval for Ravicti to treat urea cycle disorders

Study supports hypothesis that disulfiram reduces drug consumption by blocking DβH

Delaware District Court rules in favor of Pfizer in RAPAMUNE patent case

Pediatric migraine drugs show limited or no efficacy

Genzyme receives FDA approval for Kynamro to treat homozygous familial hypercholesterolemia

Childhood adversity raises comorbidity risk in bipolar disorder

Sanofi announces availability of Auvi-Q in U.S. retail pharmacies

FDA approves Pfizer’s Prevnar 13 to prevent pneumococcal disease in older children, adolescents

FDA approves Takeda’s NESINA, OSENI and KAZANO for treatment of type 2 diabetes

Takeda receives FDA approval for Nesina, Kazano and Oseni to treat type 2 diabetes

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Headache News and Research

Latest Headache News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in